(PharmaNewsWire.Com, April 17, 2021 ) According to research report the structural heart devices market is projected to reach USD 15.08 billion by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%.
The rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, increasing awareness about structural heart diseases and favorable reimbursement scenario for structural heart procedures & devices are the major factors driving the growth of the structural heart devices market.
On the basis of products, the structural heart market is segmented into heart valve devices, occluders and delivery systems, annuloplasty rings, other devices, and accessories. The heart valve devices segment is further subdivided into transcatheter heart valves and surgical heart valves. The heart valve devices segment is expected to account for the largest market share in 2018. The growing number of transcatheter aortic valve replacement procedures performed across the globe, the efficacy and durability of these products, and the growing number of regulatory approvals for heart valve devices are some of the key factors supporting the growth of this product segment.
On the basis of procedure, the market has been broadly segmented into replacement procedures and repair procedures. The replacement procedures segment is further segmented into TAVR (transcatheter aortic valve replacement) procedures and SAVR (surgical aortic valve replacement) procedures, while the repair procedures segment is subdivided into closure procedures, annuloplasty, valvuloplasty, and TMVR procedures. The replacement procedures segment is expected to account for the largest share of the structural heart devices market in 2018. This can be attributed to the long-term durability of these procedures and the widespread preference for transcatheter replacement.
Available customizations -
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis -
> Further breakdown of the Rest of Europe structural heart devices market into Russia, Sweden, Austria, Spain, and other European countries
Company Information -
> Detailed analysis and profiling of additional market players (Up to 5)
Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK) are the key players in the structural heart market. The other players in this market are CryoLife, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Micro Interventional Devices, Inc. (US), Braile Biomédica (Brazil) and TTK Healthcare Limited (India).
North America is expected to dominate the structural heart devices market during the forecast period. The large share of North America in the global market is attributed to factors such as the rising prevalence of structural heart diseases, favorable reimbursement scenario for structural heart procedures and devices, technological advancements, and development of innovative devices.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
